e-learning
resources
Stockholm 2007
Tuesday 18.09.2007
New drugs for asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients?
F. Fahimi, S. Sohrabi, H. Jamaati, Z. Mohammad Taheri, A. Fakharian, J. Salamzadeh (Tehran, Islamic Republic Of Iran)
Source:
Annual Congress 2007 - New drugs for asthma
Session:
New drugs for asthma
Session type:
Oral Presentation
Number:
2960
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
F. Fahimi, S. Sohrabi, H. Jamaati, Z. Mohammad Taheri, A. Fakharian, J. Salamzadeh (Tehran, Islamic Republic Of Iran). Does atorvastatin have effect on lung function and morbidity as add-on therapy in asthmatic patients?. Eur Respir J 2007; 30: Suppl. 51, 2960
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Anti-inflammatory effects of add-on atorvastatin therapy during the treatment of COPD patients
Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights
Year: 2012
Omalizumab improves asthma control in patients receiving high-dose ICS and multiple other controller therapies and who have continuing impairment of lung function and asthma symptoms
Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities
Year: 2007
Pleiotropic effects of add-on atorvastatin therapy during the treatment of COPD patients
Source: Annual Congress 2011 - New treatments for airway disease
Year: 2011
Effect of dupilumab on oral corticosteroid use in severe asthma patients with improving lung function
Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma
Year: 2020
The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD
Source: Eur Respir J 2004; 24: Suppl. 48, 341s
Year: 2004
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment
Source: Eur Respir J 2002; 20: Suppl. 38, 245s
Year: 2002
Once-daily tiotropium Respimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics
Source: International Congress 2017 – Clinical points to ponder in asthma
Year: 2017
The effect of tiotropium in the treatment of patients with COPD
Source: Annual Congress 2010 - COPD: management
Year: 2010
Montelukast as add-on therapy may improve some indices of small airways involvement in uncontrolled asthmatics
Source: Annual Congress 2011 - Asthma management and response
Year: 2011
Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients
Source: Eur Respir J, 53 (6) 1801824; 10.1183/13993003.01824-2018
Year: 2019
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma?
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Low-dose amiodarone therapy may be responsible of serious adverse pulmonary effects in patients without pre-existing lung disease
Source: Eur Respir J 2004; 24: Suppl. 48, 280s
Year: 2004
A rejuvenation effect of the antifibrotic therapy correlates with lung function improvement in IPF patients
Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases
Year: 2021
Efficacy of oral add-on therapy in patients with pulmonary hypertension
Source: Annual Congress 2009 - Pulmonary hypertension
Year: 2009
Does azithromycin-prednisolone combination therapy have additive effects than single therapy in patients with persistent asthma?
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009
Once-daily tiotropium Respimat add-on therapy improves lung function in children with moderate symptomatic asthma, independent of the degree of airflow obstruction
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Effect of sildenafil add-on to antifibrotic treatment in IPF patients
Source: Virtual Congress 2021 – Interstitial lung disease around the world
Year: 2021
The oral corticosteroid sparing effect of omalizumab in paediatric patients with severe chronic asthma
Source: Annual Congress 2010 - Managing asthma and allergic disease in children
Year: 2010
The effect preoperative intervention with long-acting bronchodilator for untreated patients with obstructive lung disease
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept